Fermbox Bio Announces Collaboration with Dyadic to Co-develop and Commercialise Biomaterials using Proprietary Fungal Expression Platform

Fermbox Bio, a synthetic biology company, is focused on using microbial precision fermentation, for sustainable and commercially viable production, of bio-alternatives to those derived from plants and animals, announced its collaboration agreement with Dyadic International Inc. This collaboration will bring together Fermbox’s extensive product development and scale up process engineering capabilities and Dyadic’s proprietary Dapibus™ filamentous fungal based microbial protein production platform and to design, develop and commercialize innovative animal free alternative proteins and biomaterials.

“We are very excited to partner with Dyadic and use its novel Dapibus™ platform to create alternative biomaterials that are not only sustainable but also economically viable. Our joint expertise across expression systems and execution capabilities from lab to large scale manufacturing, uniquely positions us for success. We have a long-standing relationship with Dyadic leadership, and we believe that this co-development agreement can potentially accelerate the timelines for both companies to bring new and commercially viable bio-alternates to the market sooner,” commented Mr. Subramani (suBBu) Ramachandrappa, Founder of Fermbox Bio. “Having operations both in the US and in India, Fermbox is uniquely positioned to collaborate globally and use its advantage of access to Indian scientific talent and manufacturing capabilities locally. We are of the opinion that the synthetic biology industry will follow our model to increase success rates for product development and viable commercialization. We are pleased to embark on this journey with Dyadic and are keen to put our collaboration to work, bringing our complementary skills to action.”

“I am excited to announce this fully funded co-development and marketing agreement with Fermbox which is consistent with our business strategy of focusing on near term commercialization opportunities that can create shareholder value,” said Joe Hazelton, Chief Business Officer of Dyadic. “Fermbox has extensive expertise in bio-alternate development and microbial precision fermentation which we expect will accelerate our ability to exploit the DapibusTM platform and expand Dyadic’s product offerings for non-pharmaceutical alternative proteins applications, such as food, nutrition, wellness and other bioproducts. We anticipate this collaboration will enhance our market penetration into the alternative protein markets at the same time our biopharmaceutical activities using C1 are also advancing at a rapid pace. We believe that this collaboration will further leverage our proprietary DapibusTM platform toward developing and commercializing multiple end-market animal free protein products.”

About Fermbox Bio

Fermbox Bio, a synthetic biology company with operations in USA and India, is focused on using microbial precision fermentation, for sustainable and commercially viable production, of bio-alternatives to those derived from plants and animals.

Leveraging its expertise across microbial expression systems, and experience from clone development to large-scale Bio-manufacturing, Fermbox Bio has evolved a de-risked collaborative model to co-develop, manufacture and commercialize biomaterials for the global market. These biomaterials are used in food, cosmeceutical, nutraceutical and industrial applications.

The Fermbox team comes together with a shared commitment to positively impacting the planet and a passion for innovation.

To learn more about Fermbox Bio’s focus areas or its collaborative business model, please visit www.fermbox.bio or write to Info@fermbox.bio.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). The lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. 

To learn more about Dyadic please visit https://www.dyadic.com.

Share This Post